TENAYA THERAPEUTICS INC. - COMMON STOCK

Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

08 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

26 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

09 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

05 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

02 Oct 2023 16:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

21 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference

31 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

09 Aug 2023 15:05:01 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference

02 Aug 2023 15:05:02 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

10 May 2023 15:19:57 By Nasdaq GlobeNewswire

Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting

03 May 2023 07:00:01 By Nasdaq GlobeNewswire

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

02 May 2023 06:50:18 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

21 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

08 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

07 Feb 2023 16:17:05 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones

09 Jan 2023 06:00:02 By Nasdaq GlobeNewswire

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

07 Dec 2022 15:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy

28 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

23 Nov 2022 08:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Closing of Public Offering

21 Nov 2022 16:45:00 By Nasdaq GlobeNewswire